Covidien AG Sustainability Profile
Covidien AG, a prominent player in the global healthcare sector, is headquartered in Switzerland (CH) and operates extensively across Europe, North America, and Asia. Founded in 2000, the company has established itself as a leader in the medical device and supplies industry, focusing on innovative solutions for surgical and medical applications. Specialising in advanced surgical instruments, respiratory products, and medical imaging technologies, Covidien AG is renowned for its commitment to quality and innovation. The company’s unique offerings, such as minimally invasive surgical devices, have significantly enhanced patient outcomes and operational efficiency in healthcare settings. With a strong market position, Covidien AG has achieved numerous accolades for its contributions to medical technology, solidifying its reputation as a trusted partner in the healthcare community.
DitchCarbon Score
How does Covidien AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Land Transportation industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Covidien AG's score of 38 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Covidien AG, headquartered in Switzerland (CH), currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of Medtronic plc, which influences its climate commitments and reporting practices. Covidien AG's climate initiatives and reduction targets are inherited from its parent company, Medtronic plc. Medtronic has established various sustainability goals, including commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets for Covidien AG have not been detailed. As part of its corporate family, Covidien AG aligns with Medtronic's broader climate strategies, which focus on reducing greenhouse gas emissions across all scopes. The absence of direct emissions data highlights the need for ongoing transparency and commitment to climate action within the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 74,992,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 269,008,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | - |
How Carbon Intensive is Covidien AG's Industry?
How Carbon Intensive is Covidien AG's Location?
Covidien AG's Scope 3 Categories Breakdown
Covidien AG's Scope 3 emissions, which increased by 48% last year and increased by approximately 48% since 2021, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 55% of total emissions under the GHG Protocol, with "Downstream Transportation & Distribution" being the largest emissions source at 47% of Scope 3 emissions.
Top Scope 3 Categories
Covidien AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Covidien AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
